Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Apr 1;45(2):133-135.
doi: 10.1097/FTD.0000000000001062. Epub 2023 Jan 11.

Doravirine Exposure Decreased by Dialysis in a HIV Patient: A Grand Round

Yeleen Fromage  1 , Cyrielle Codde  2 , Caroline Monchaud  1   3 , Marc Labriffe  1   3 , Minh P Lê  4   5 , Jean-François Faucher  2 , Jean-Baptiste Woillard  1   3
Affiliations
Free article
Case Reports

Doravirine Exposure Decreased by Dialysis in a HIV Patient: A Grand Round

Yeleen Fromage et al. Ther Drug Monit. .
Free article

Abstract

Background: The authors report the case of a 66-year-old male patient who was hemodialyzed 3 times per week for chronic renal failure and treated with 100 mg of doravirine once daily in combination with dolutegravir for HIV-1. No dose adjustment is required for doravirine in cases of severe renal injury, but the effect of dialysis on its exposure is poorly understood.

Methods results: Two series of 2 samples were drawn before and after 4-hour hemodialysis and showed an average doravirine concentration decrease of 48.1 ± 6.7%. The effects of hemodialysis were important, contrary to what was expected and has been previously reported. In addition, intraindividual variability was low. Nevertheless, because the concentrations reported were largely above the inhibitory concentration 50 (IC 50 ), no dose adjustment was required.

Conclusions: The decrease in doravirine concentration due to hemodialysis observed in this case report was quite significant. Therefore, therapeutic drug monitoring might be recommended in certain patients undergoing doravirine treatment also on hemodialysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ankrom W, Yee KL, Sanchez RI, et al. Severe renal impairment has minimal impact on doravirine pharmacokinetics. Antimicrob Agents Chemother. 2018;62:003266–e418.
    1. Côté B, Burch JD, Asante-Appiah E, et al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett. 2014;24:917–922.
    1. Pifeltro EMA. European medicines agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/pifeltro . Accessed August 24, 2022.
    1. Moltó J, Graterol F, Curran A, et al. Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease. J Antimicrob Chemother. 2022;77:1989–1991.
    1. Moltó J, Graterol F, Miranda C, et al. Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage renal disease. Antimicrob Agents Chemother. 2016;60:2564–2566.

Publication types